Sector portfolio · Private equity · United States

Cormorant Asset Management's Pharma portfolio

Cormorant Asset Management has backed 14 Pharma startups in rounds we track, $2.6B between them, shown by the stage each has reached. The best-funded is Parabilis Medicines.

14startups backed
3stages
$2.6Braised between them
Stage not reportedbiggest stage

Cormorant Asset Management's whole portfolioCormorant Asset Management's profile

Stage not reported

7

Series C and later

4

Series B

3

Segment by segment

Stage not reported

7 startups · $1.1B raised

  1. AutolusAutolus is a biopharmaceutical company focused on T-cell programming and manufacturing technology.United Kingdom$350M
  2. GH ResearchGH Research is a biopharmaceutical company developing novel therapies for the management of mental illness.Ireland$268M
  3. Edgewise TherapeuticsEdgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.United States$200M
  4. Tessera TherapeuticsTessera Therapeutics, Inc.United States$150M
  5. Interius BioTherapeuticsInterius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas.United States$73M
  6. Elevation OncologyElevation Oncology is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients.United States$50M
  7. Ventyx BiosciencesVentyx is a biopharmaceutical company focused on advancing oral therapies for patients living with autoimmune and inflammatory disorders.United States$27M

Series C and later

4 startups · $751M raised

  1. Parabilis MedicinesParabilis Medicines is a Grupo Bugio is a biopharmaceutical firm that specializes in creating medicines.United States$380M
  2. Ovid TherapeuticsOvid Therapeutic's purpose is to solve intractable medical problems.United States$166M
  3. Elpiscience BiopharmaceuticalsElpiscience Biopharmaceuticals is a clinical-stage biopharmaceutical company based in Shanghai, China, founded in 2017.China$105M
  4. Umoja BiopharmaUmoja Biopharma is a clinical-stage biotechnology company based in Seattle, Washington, founded in 2019.United States$100M

Series B

3 startups · $708M raised

  1. CTCrystalys TherapeuticsUnited States$335M
  2. Corvus PharmaceuticalsCorvus Pharmaceuticals is a clinical-stage biopharmaceutical company.United States$310M
  3. Rain OncologyRain Oncology is a clinical-stage company focusing on research and development of innovative therapies for cancer patients.-$63M

How this map is made. Every startup here works in Pharma and has raised money in a round we track that names Cormorant Asset Management as an investor. Each sits under the stage of its latest round. Rebuilt nightly; updated 15 November 2026.

More portfolio maps

All portfolios
Sector portfolioCormorant Asset Management's Biotech portfolio95 startups · $21BSector portfolioCormorant Asset Management's Healthtech portfolio12 startups · $1.1BPortfolio mapCormorant Asset Management portfolio map123 startups · $25BCo-investorsWho invests with Cormorant Asset Management97 co-investorsSector portfolioRA Capital Management's Biotech portfolio197 startups · $38BSector portfolioOrbiMed's Biotech portfolio176 startups · $28B

Raising from investors like Cormorant Asset Management?

Find the investors who back startups like yours, with their cheques, rounds and partners, in the app with filters, lists and exports.

Find investorsMarket maps